Retirement Systems of Alabama Sells 4,152 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Retirement Systems of Alabama reduced its Medpace stake by 6.6%, selling 4,152 shares and retaining 59,199 shares valued at approximately $31.4 million. Institutional investors collectively own 77.98% of the company.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. The company provided fiscal 2026 EPS guidance of $17.25–$17.95.
• Medpace shares opened at $581.95, while the analyst consensus remains “Hold” with a $584.18 price target. Insiders have sold 55,371 shares worth about $30.9 million over the past 90 days.

Retirement Systems of Alabama trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,199 shares of the company's stock after selling 4,152 shares during the period. Retirement Systems of Alabama owned approximately 0.21% of Medpace worth $31,351,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock valued at $168,198,000 after purchasing an additional 183,645 shares during the last quarter. Norges Bank acquired a new position in shares of Medpace during the 4th quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company's stock worth $194,920,000 after buying an additional 166,654 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Stock Down 2.5%

NASDAQ MEDP opened at $581.95 on Friday. The company has a market cap of $16.24 billion, a price-to-earnings ratio of 34.11, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The business's fifty day moving average is $533.75 and its 200 day moving average is $491.74.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 17,610 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the sale, the chief executive officer directly owned 615,802 shares of the company's stock, valued at $372,627,948.22. The trade was a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 55,371 shares of company stock worth $30,878,030. 20.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on MEDP shares. TD Cowen raised their price objective on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Truist Financial increased their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source